IL-1, EGF, and HGF suppress the antiviral activity of interferon in primary monkey hepatic parenchymal cells

Japanese Journal of Infectious Diseases

Volumn 52, Issue 2, 1999, Pages 45-48

  Takahara, Toshio ^a   Fukuyama, Yasuhiro ^a   Saito, Sakura ^a   Ogino, Toshio ^a   Miyajima, Naoko ^a   Kohase, Masayoshi ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; EPIDERMAL GROWTH FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; DRUG INHIBITION; HEPATITIS C; HEPATITIS C VIRUS; LIVER PARENCHYMA; MONKEY; NONHUMAN; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; EPIDERMAL GROWTH FACTOR; FEMALE; GROWTH SUBSTANCES; HAPLORHINI; HEPACIVIRUS; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; INTERLEUKIN-1; INTERLEUKIN-6; LIVER;

EID: 0032878061     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Yamada, G., Takatani, M., Kishi, F., Takahashi, M., Doi, T., Tsuji, T., Shin, S., Tanno, M., Urdea, M. S. and Kolberg, J. A. (1995): Efficacy of Interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology, 22, 1351-1354.
2. Kanai, K., Kako, M. and Okamoto, H. (1992): HCV genotypes in chronic hepatitis C and response to interferon. Lancet, 339, 1543.
3. Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T., Yamamoto, C., Izumi, N., Marumo, F. and Sato, C. (1995): Comparison of full-length sequences of interferon-sensitive and -resistant hepatitis C virus 1b. J. Clin. Invest., 96, 224-230.
4. Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T., Yamamoto, C., Ogura, Y., Izumi, N., Marumo, F. and Sato, C. (1996): Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med., 334, 77-81.
5. Thiel, D. H. V., Friedlander, L., Fagiuoli, S., Wright, H. I., Irish, W. and Gavaler, J. S. (1994): Response to interferon a therapy is influenced by the iron content of the liver. Hepatology, 20, 410-415.
6. Clemente, M. G., Congia, M., Lai, M. E., Lilliu, F., Lampis, R., Frau, F., Frau, M. R., Faa, G., Diana, G., Dessi, C., Melis, A., Mazzoleni, A. P., Cornacchia, G., Cao, A. and Virgiliis, S. de. (1994): Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J. Pedatr., 125, 123-128.
7. Bonkovsky, H. L., Ponka, P., Bacon, B. R., Drysdale, J., Grace, N. D. and Tavill, A. S. (1996): An update on iron metabolism: Summary of the fifth international conference on disorders of iron metabolism. Hepatology, 24, 718-729.
8. Kohase, M., Henrikson-Destefano, D., May, L. T., Sehgal, P. B. and Vilcek, J. (1986): Induction of β2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation. Cell, 45, 659-666.
9. Kohase, M., May, L. T., Tamm, I., Vilcek, J. and Sehgal, P. B. (1987): A cytokine network in human diploid fibroblasts: Interaction of β-interferons, tumor necrosis factor, platelet-derived growth factor, and interleukin-1. Mol. Cell. Biol., 7, 273-280.
10. Oleszak, E. and Inglot, A. D. (1980): Platelet-derived growth factor inhibits antiviral and anticellular action of interferon in synchronized mouse or human cells. J. Interferon Res., 1, 37-48.
11. Kohase, M., Zhang, Y., Lin, Jian-Xin., Yamazaki, S., Sehgal, P. B. and Vilcek, J. (1988): Interleukin-1 can inhibit interferon-β synthesis and its antiviral action: comparison with tumor necrosis factor. J. Interferon Res., 8, 559-570.
12. Kohase, M., Enami, K., Matsuura, Y. and Yamazaki, S. (1989): The biology of interferon system 1988. p.283-288. In Y. Kawade and S. Kobayashi (eds.), Interferon cytokine (TNF, IL-1, EGF, PDGF, IFN-beta2/IL-6) system in human diploid fibroblast (FS-4) cells. Kodansha Scientific Ltd., Tokyo.
13. Berry, M. N. and Friend, D. S. (1989): High-yield preparation of isolated rat liver parenchymal cells. A biochemical and structural study. J. Cell. Biol., 43, 506-520.
14. Akira, S., Hirano, T., Taga, T. and Kishimoto, T. (1990): Biology of multifunctional cytokines: IL 6 and related molecules (IL-1 and TNF). FASEB J., 4, 2860-2867.
15. Koj, A., Gauldie, J., Regoeczi, E., Sauder, D. N. and Sweeney, G. D. (1984): The acute-phase response of cultured rat hepatocytes. System characterization and the effect of human cytokines. Biochem. J., 224, 505-514.
16. Larrea, E., Garcia, N., Qian, C., Civeira, M. P. and Prieto, J. (1996): Tumor necrosis factor α gene expression and the response to interferon in chronic hepatitis C. Hepatology, 23, 210-217.
17. Mihm, S., Hutschenreiter, A., Fayyazi, A., Pingel, S. and Ramadori, G. (1996): High inflammatory activity is associated with an increased amount of IFN-γ transcripts on peripheral blood cells of patients with chronic hepatitis C virus infection. Med. Microbiol. Immunol., 185, 95-102.
18. Cacciarelli, T. V., Martinez, O. M., Gish, R. G., Villanueva, J. C. and Krams, S. M. (1996): Immunoregulatory cytokines in chronic hepatitis C Virus infection: Pre- and posttreatment with interferon alfa. Hepatology, 24, 6-9.
19. Nakamura, T., Teramoto, H. and Ichihara, A. (1986): Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc. Natl. Acad. Sci. USA, 83, 6489-6493.
20. Michalopoulos, G. K. and Zarneger, R. (1992): Hepatocyte growth factor. Hepatology, 15, 149-155.
21. Masuhara, M., Yasunaga, M., Tanigawa, K., Tamura, F., Yamashita, S., Sakaida, I. and Okita, K. (1996): Expression of hepatocyte growth factor, transforming growth factor alfa, and transforming growth factor beta messenger RNA in various human liver diseases and correlation with hepatocyte proliferation. Hepatology, 24, 323-329.
22. Mead, J. E. and Fausto, N. (1989): Transforming growth factor α may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc. Natl. Acad. Sci. USA, 86, 1558-1562.
23. Kamimura, S. and Tsukamoto, H. (1995): Cytokine gene expression by kupffer cells in experimental alcoholic liver disease. Hepatology, 22, 1304-1305.
24. Webber, E. M., Fitzgerald, M. J., Brown, P. I., Bartlett, M. H. and Fausto, N. (1993): Transforming growth factor-α expression during liver regeneration after partial hepatectomy and toxic injury, and potential interactions between transforming growth factor-α and hepatocyte growth factor. Hepatology, 18, 1422-1431.
25. Berry, M. N. and Friend, D. S. (1989): High-yield preparation of isolated rat liver parenchymal cells. A biochemical and structural study. J. Cell. Biol., 43, 506-520.
26. Nakamura, T., Teramoto, H. and Ichihara, A. (1986): Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc. Natl. Acad. Sci. USA, 83, 6489-6493.
27. Johnson, A. C., Garfield, S. H., Merlino, G. T. and Pastan, I. (1988): Expression of epidermal growth factor receptor protooncogene mRNA in regenerating rat liver. Biochem. Biophys. Res. Commun., 150, 412-418.
28. Braun, L., Mead, J. E., Panzica, M., Mikumo, R., Bell, G. I. and Fausto, N. (1988): Transforming growth factor β mRNA increases during liver regeneration: a possible paracrine mechanism of growth regulation. Proc. Natl. Acad. Sci. USA, 85, 1539-1543.
29. Nakamura, T., Arakaki, R. and Ichihara, A. (1988): Interleukin-1 β is a potent growth inhibitor of adult rat hepatocytes in primary culture. Exp. Cell Res., 179, 488-497.
30. Castilla, A., Prieto, J. and Fausto, N. (1991): Transforming growth factor β 1 and α in chronic liver disease: effects of interferon alfa therapy. N. Engl. J. Med., 324, 933-940.
31. Masaague, J. (1983): Epidermal growth factor-like transforming growth factor II. Interaction with epidermal growth factor receptors in human placenta membrans and A431 cells. J. Biol. Chem., 258, 13614-13620.
32. Marquardt, H., Hunkapiller, M. W., Hood, L. E. and Todaro, G. J. (1984). Rat transforming growth factor type 1: structure and relation to epidermal growth factor. Science, 223, 1079-1082.
33. Kerr, I. M. and Stark, G. R. (1992): The antiviral effects of interferons and their inhibition. J. Interferon Res., 12, 237-240.
34. Peters, M. (1996): Action of cytokines on the immune response and viral interactions: An overview. Hepatology, 23, 909-916.
35. Ikeda, T., Lever, A. M. L. and Thomas, H. C. (1986): Evidence for a deficiency of interferon Production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology, 6, 962-965.
36. Onji, M., Lever, A. M. L., Saito, I. and Thomas, H. C. (1989): Defective response to interferons in cells transfected with the hepatitis B virus genome. Hepatology, 9, 92-96.
37. Ikeda, T., Pigntelli, M., Lever, A. M. L. and Thomas, H. C. (1986): Relationship of HLA protein display to activation of 2-5A synthetase in HBe antigen or anti-HBe positive chronic HBV infection. Gut, 27, 1498-1501.
38. Whitten, T. M., Quets, A. T., and Schloemer, R. H. (1991): Identification of the hepatitis B virus factor that inhibits expression of the beta interferon gene. J. Virol., 65, 4699-4704.
39. Gale, Jr. M. J., Korth, M. J., Tang, M. N., Tan, S. J., Hopkins, D. A., Dever, Y. E., Polyac, S. J., Gretch, D. R. and Katze, M. G. (1997): Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructual 5A protein. Virology, 230, 217-227.
40. Gale, M. J., Jr., Biakely, C. M., Kwieciszewski, B., Tan, S-L., Dossett, M., Tang, N. M., Korth, M. J., Polyak, S. J., Gretch, D. R. and Katze, M. G. (1998): Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation. Mol. Cell. Biol., 18, 5208-5218.